Straits Times Index
3,156.21+17.24(+0.55%)Nikkei
27,950.17+116.88(+0.42%)Hang Seng
25,890.92-301.40(-1.15%)FTSE 100
7,025.43-2.15(-0.03%)BTC-USD
36,728.47-1,583.60(-4.13%)CMC Crypto 200
867.72-47.77(-5.22%)
Emergent BioSolutions Inc. (EBS)
After hours: 06:33PM EDT
| Previous close | 64.39 |
| Open | 64.39 |
| Bid | 60.70 x 1200 |
| Ask | 63.95 x 800 |
| Day's range | 62.16 - 64.39 |
| 52-week range | 55.07 - 137.61 |
| Volume | 233,840 |
| Avg. volume | 681,838 |
| Market cap | 3.342B |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | 8.76 |
| EPS (TTM) | 7.12 |
| Earnings date | 29 Jul 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 92.17 |
- Zacks
Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Can Emergent BioSolutions Recover From Its Recent Blunders?
Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not Emergent BioSolutions can recover from its recent blunders. Brian Orelli: Yes, they can fix the issues that they had with the manufacturing and get better management in there to make sure that they're following all the FDA rules and good manufacturing practices.
- Motley Fool
Why Johnson & Johnson Is Trashing 60 Million Doses of Its COVID Vaccine
Johnson & Johnson (NYSE: JNJ) hasn't become the major player in the COVID-19 vaccine market that many expected it to be, in large part because of manufacturing issues at a contractor's facility. Now, those issues have become even worse, and the Food and Drug Administration has told the healthcare giant that it must discard 60 million doses of its COVID-19 vaccine. In this Motley Fool Live video recorded on June 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why J&J is having to dump these vaccine doses.
